The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
An open-label, randomized, parallel-group study of the pharmacokinetics of trifluridine as a component of TAS-102 versus FTD alone.
 
Weijing Sun
No Relationships to Disclose
 
Lee S. Rosen
Research Funding - Lilly (Inst); Pfizer (Inst); Regeneron (Inst)
 
Drew W. Rasco
Research Funding - Asana Biosciences (Inst); Bayer (Inst); Celgene (Inst); Five Prime Therapeutics (Inst); Millennium (Inst); Pharmacyclics (Inst); Rexahn Pharmaceuticals (Inst); Santa Maria Biotherapeutics (Inst); Taiho Pharmaceutical (Inst); Teva (Inst)
 
Kenichiro Yoshida
Employment - Taiho Pharmaceutical
 
Jabed Seraj
Employment - Taiho Pharmaceutical
Patents, Royalties, Other Intellectual Property - Johnson & Johnson; Merck
 
Geoffrey Shapiro
Consulting or Advisory Role - Chugai Pharma; G1 Therapeutics; Vertex
Research Funding - AstraZeneca (Inst); Bayer (Inst); Cellceutix (Inst); Covidien (Inst); Cyclacel (Inst); Genentech (Inst); Immune Design (Inst); Millennium (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Pfizer (Inst); Puma Biotechnology (Inst); Sanofi (Inst); Tensha Therapeutics (Inst); Vertex (Inst)
 
James M. Cleary
No Relationships to Disclose